Advanced search
Publication Cover
Emerging Microbes & Infections Volume 5, 2016 - Issue 1
Submit an article Journal homepage
2,824
Views
51
CrossRef citations to date
0
Altmetric
Original Articles

Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria

Wei SunNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD20892, USA
,
Rebecca A WeingartenDepartment of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, MD20892, USACorrespondence[email protected] [email protected] [email protected]
,
Miao XuNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD20892, USA
,
Noel SouthallNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD20892, USA
,
Sheng DaiNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD20892, USA
,
Paul ShinnNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD20892, USA
,
Philip E SandersonNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD20892, USA
,
Peter R WilliamsonLaboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD20892, USACorrespondence[email protected] [email protected] [email protected]
,
Karen M FrankDepartment of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, MD20892, USACorrespondence[email protected] [email protected] [email protected]
&
Wei ZhengNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD20892, USACorrespondence[email protected] [email protected] [email protected]
 show all
Pages 1-11 | Received 01 Jul 2016, Accepted 28 Aug 2016, Published online: 25 Jan 2019

  • Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: CDC, 2016; Available at http://www.cdc.gov/drugresistance/threat-report-2013/(accessed on 15 June 2016).
  • LevySB,MarshallB.Antibacterial resistance worldwide: causes, challenges and responses.Nat Med2004 Dec; 10(12 Suppl):S122–S129.
  • JorgensenJH,FerraroMJ.Antimicrobial susceptibility testing: a review of general principles and contemporary practices.Clin Infect Dis2009; 149:1749–1755.
  • WorthingtonRJ,MelanderC.Combination approaches to combat multidrug-resistant bacteria.Trends Biotechnol2013 Mar; 31:177–184.
  • PoulikakosP,TansarliGS,FalagasME.Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review.Eur J Clin Microbiol Infect Dis2014; 33:1675–1685.
  • ZilberbergMD,ShorrAF,MicekST,Vazquez-GuillametC,KollefMH.Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study.Crit Care2014; 18:6.
  • SmithKP,KirbyJE.Verification of an automated, digital dispensing platform for at-will broth microdilution antimicrobial susceptibility testing.J Clin Microbiol2016; 54:2288–2293.
  • Cornejo-JuarezP,Vilar-CompteD,Perez-JimenezC,Namendys-SilvaSA,Sandoval-HernandezS,Volkow-FernandezP.The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit.Int J Infect Dis2015; 31:31–34.
  • Garnacho-MonteroJ,Aldabo-PallasT,Garnacho-MonteroCet al.Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis.Crit Care2006; 10:R111.
  • BrownD.Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?Nat Rev Drug Discov2015; 14:821–832.
  • PowersJH.Antimicrobial drug development - the past, the present, and the future.Clin Microbiol Infec2004; 10:23–31.
  • ChromyBA,ElsheikhM,ChristensenTL,et al.Repurposing screens identify rifamycins as potential broad-spectrum therapy for multidrug-resistant Acinetobacter baumannii and select agent microorganisms.Future Microbiol2012; 7:1011–1020.
  • FengJ,WangT,ShiWL,et al.Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library.Emerg Microbes Infect2014; 3:e49.
  • HarbutMB,VilchezeC,LuoX,et al.Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis.Proc Natl Acad Sci USA2015; 7112:4453–4458.
  • DeakD,OuttersonK,PowersJH,KesselheimAS.Progress in the fight against multidrug-resistant bacteria? A review of U.S. Food and Drug Administration-approved antibiotics, 2010-2015.Ann Intern Med2016; 165:363–372.
  • HuangRL,SouthallN,WangYH,et al.The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.Sci Transl Med2011; 380ps16.
  • TangKC,ReboudJ,KwokYL,PengSL,YobasL.Lateral patch-clamping in a standard 1536-well microplate format.Lab Chip2010; 10:1044–1050.
  • GieraM,HeusF,JanssenL,KoolJ,LingemanH,IrthH.Microfractionation revisited: a 1536 well high resolution screening assay.Anal Chem2009; 181:5460–5466.
  • ChenS,HsiehJH,HuangRet al.Cell-based high-throughput screening for aromatase inhibitors in the Tox21 10 K library.Toxicol Sci2015; 147:446–457.
  • IngleseJ,AuldDS,JadhavA,et al.Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.Proc Natl Acad Sci USA2006; 1103:11473–11478.
  • HardimanCA,WeingartenRA,ConlanSet al.Horizontal transfer of carbapenemase-encoding plasmids and comparison with hospital epidemiology data.Antimicrob Agents Chemother2016; 60:4910–4919.
  • HuangR,SouthallN,WangY,et al.The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.Sci Transl Med2011; 3:80ps16.
  • SunW,TanakaTQ,MagleCT,et al.Chemical signatures and new drug targets for gametocytocidal drug development.Sci Rep2014; 4:3743.
  • Clinical Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-10th ed. Document M07-A10., vol. 35. Wayne, PA: CLSI, 2015.
  • ZhaoW,SachsenmeierK,ZhangLJ,SultE,HollingsworthRE,YangH.A new bliss independence model to analyze drug combination data.J Biomol Screen2014; 19:817–821.
  • SunW,ParkYD,SuguiJA,et al.Rapid identification of antifungal compounds against Exserohilum rostratum using high throughput drug repurposing screens.Plos ONE2013; 8: e70506.
  • TitusSA,BeachamD,ShahaneSAet al.A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.Anal Biochem2009; 1394:30–38.
  • WalkerPD,BarriY,ShahSV.Oxidant mechanisms in gentamicin nephrotoxicity.Ren Fail1999; 21:433–442.
  • EUCAST.Breakpoint tables for interpretation of MICs and zone diameters, version 4.0.Växjö, Sweden: EUCAST Laboratory for Antimicrobial Susceptibility Testing.2014.
  • AguinagaldeL,Diez-MartinezR,YusteJet al.Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections.J Antimicrob Chemother2015; 70:2608–2617.
  • SchonT,JureenP,ChryssanthouE,et al.Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?J Antimicrob Chemother2013; 68:2074–2077.
  • HeS,LinB,ChuV,et al.Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.Sci Transl Med2015; 7:282ra249.
  • MitsuyaH,WeinholdKJ,FurmanPA,et al.3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.Proc Natl Acad Sci USA1985; 82:7096–7100.
  • LisewskiAM,QuirosJP,NgCLet al.Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate.Cell2014; 158:916–928.
  • JeonKI,ByunMS,JueDM.Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit.Exp Mol Med2003; 35:61–66.
  • SiegenthalerPA,PackerL.Light-dependent volume changes and reactions in chloroplasts. I. Action of alkenylsuccinic acids and phenylmercuric acetate and possible relation to mechanisms of stomatal control.Plant Physiol1965; 40:785–791.
  • ReederNL,XuJ,YoungquistRS,SchwartzJR,RustRC,SaundersCW.The antifungal mechanism of action of zinc pyrithione.Br J Dermatol2011; 165(Suppl 2):9–12.
  • PovirkLF,WubterW,KohnleinW,HutchinsonF.DNA double-strand breaks and alkali-labile bonds produced by bleomycin.Nucleic Acids Res1977; 4:3573–3580.
  • FrederickJJ,CornerTR,GerhardtP.Antimicrobial actions of hexachlorophene: inhibition of respiration in Bacillus megaterium.Antimicrob Agents Chemother1974; 6:712–721.
  • SiegelD.Tetracyclines: new look at old antibiotic. I. Clinical pharmacology, mechanism of action, and untoward effects.NY State J Med1978; 78:950–956.
  • QureshiZA,PatersonDL,PotoskiBA,et al.Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.Antimicrob Agents Chemother2012; 56:2108–2113.
  • AnderssonDI,HughesD.Antibiotic resistance and its cost: is it possible to reverse resistance?Nat Rev Microbiol2010; 8:260–271.
  • SunW,SandersonP,ZhengW.Drug combination therapy increases successful drug repositioning.Drug Discov Today2016; 21:1189–1195.
  • RoderC,ThomsonMJ.Auranofin: repurposing an old drug for a golden new age.Drugs R D2015; 15:13–20.
  • CrabolY,CatherinotE,VezirisN,JullienV,LortholaryO.Rifabutin: where do we stand in 2016?J Antimicrob Chemother2016; 71:1759–1771.
  • Durante-MangoniE,SignorielloG,AndiniR,et al.Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.Clinical Infectious Diseases2013; 57:349–358.
  • DoernCD.When does 2 plus 2 equal 5? a review of antimicrobial synergy testing.J Clin Microbiol2014; 52:4124–4128.
  • AaronSD,VandemheenKL,FerrisW,et al.Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial.Lancet2005; 366:463–471.
  • AaronSD.Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms.Paediatr Respir Rev2007; 8:256–261.
  • DicksteinY,LeiboviciL,YahavD,et al.Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.BMJ Open2016; 6:e009956.
  • WistubaII,GelovaniJG,JacobyJJ,DavisSE,HerbstRS.Methodological and practical challenges for personalized cancer therapies.Nat Rev Clin Oncol2011; 8:135–141.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.